Regeneron Pharmaceuticals (REGN) Cash & Equivalents (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Cash & Equivalents of $2.5 billion for Q2 2026, up 23.05% year-over-year from $2.0 billion in Q2 2025, and down 17.11% quarter-over-quarter from $3.0 billion in Q1 2026.
Regeneron Pharmaceuticals (REGN) Cash & Equivalents (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Cash & Equivalents history runs 18 years deep, the most recent figure standing at $2.5 billion for Q2 2026.
- In Q2 2026, Cash & Equivalents rose 23.05% year-over-year to $2.5 billion; the TTM figure through Jun 2026 stood at $2.5 billion (up 23.05% YoY), while the FY2025 annual figure was $3.1 billion, up 25.32% from the prior year.
- Cash & Equivalents for Q2 2026 stood at $2.5 billion, down from $3.0 billion in the prior quarter.
- The five-year high for Cash & Equivalents was $3.9 billion in Q1 2023, with the low at $1.9 billion in Q2 2024.
- The 5-year median for Cash & Equivalents is $2.7 billion (2023), against an average of $2.7 billion.
- The sharpest annual moves came in 2022 and 2023: Cash & Equivalents surged 132.68% in 2022, then slumped 42.94% in 2023.
- Regeneron Pharmaceuticals' Cash & Equivalents stood at $3.1 billion in 2022, then decreased by 12.1% to $2.7 billion in 2023, then fell by 8.86% to $2.5 billion in 2024, then gained by 25.32% to $3.1 billion in 2025, then declined by 21.24% to $2.5 billion in 2026.
- Business Quant data shows REGN's Cash & Equivalents at $2.5 billion in Q2 2026, $3.0 billion in Q1 2026, and $3.1 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 1.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.46 Bn |
| Mar 31, 2026 | 2.96 Bn |
| Dec 31, 2025 | 3.12 Bn |
| Sep 30, 2025 | 2.51 Bn |
| Jun 30, 2025 | 2.00 Bn |
| Mar 31, 2025 | 3.09 Bn |
| Dec 31, 2024 | 2.49 Bn |
| Sep 30, 2024 | 2.01 Bn |
| Jun 30, 2024 | 1.92 Bn |
| Mar 31, 2024 | 2.60 Bn |
| Dec 31, 2023 | 2.73 Bn |
| Sep 30, 2023 | 2.15 Bn |
| Jun 30, 2023 | 1.94 Bn |
| Mar 31, 2023 | 3.92 Bn |
| Dec 31, 2022 | 3.11 Bn |
| Sep 30, 2022 | 3.49 Bn |
| Jun 30, 2022 | 3.40 Bn |
| Mar 31, 2022 | 3.35 Bn |
| Dec 31, 2021 | 2.89 Bn |
| Sep 30, 2021 | 3.43 Bn |